Evidence for a "window of opportunity" in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicenter cohort study
- Authors: Marzano, A V; Genovese, G; Casazza, G; Moltrasio, C; Dapavo, P; Micali, G; Sirna, R; Gisondi, P; Patrizi, A; Dini, V; Bianchini, D; Bianchi, L; Fania, L; Prignano, F; Offidani, A; Atzori, L; Bettoli, V; Cannavò, S P; Venturini, M; Bongiorno, M R; Costanzo, A; Fabbrocini, G; Peris, K
- Publication year: 2020
- Type: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/401854
Abstract
The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far.